1
|
Hardt SE, Eicken A, Berger F, Schubert S, Carminati M, Butera G, Grohmann J, Höhn R, Nielsen-Kudsk JE, Hildick-Smith D, Settergren M, Thomson JD, Geis N, Søndergaard L. Closure of patent foramen ovale defects using GORE® CARDIOFORM septal occluder: Results from a prospective European multicenter study. Catheter Cardiovasc Interv 2017; 90:824-829. [PMID: 28296023 DOI: 10.1002/ccd.26993] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Revised: 01/15/2017] [Accepted: 01/28/2017] [Indexed: 01/24/2023]
Abstract
AIMS The GORE® CARDIOFORM Septal Occluder (GSO) is a novel device designed for rapid and effective closure of patent foramen ovale (PFO) which has distinctive features making it suitable for a broad spectrum of anatomical variations. We report the procedural and 6 months follow-up results of the first prospective, multicenter study using GSO. METHODS AND RESULTS This single-arm study included 150 subjects undergoing closure of PFO in 10 European centers. In 149 out of 150 patients implantation of a GSO device was successful. One patient had a different PFO-closure device implanted. Periprocedural complications were few including one patient with suspected transient ischemic attack, two access site bleedings, and one patient with AV-fistula. No device embolization occurred. During the 6-month follow-up period one patient had a transient asymptomatic thrombus on the device and four patients (2.6%) were diagnosed new onset paroxysmal atrial fibrillation, which were successfully treated. No thrombembolic events occurred. Closure was successful in 94.2% of subjects at discharge evaluation and 96.9% at 6 months follow-up. CONCLUSION This prospective, multicenter study adds to previous published data and suggests that GSO is a versatile device for PFO closure with high procedural and closure success rates and low complication rates through mid-term follow-up. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Stefan E Hardt
- Department of Cardiology, Angiology, and Pulmology, University of Heidelberg, Heidelberg, Germany.,Center for Cardiac and Circulatory Diseases, Bruchsal, Germany
| | - Andreas Eicken
- Department of Pediatric Cardiology and Congenital Heart Disease, Deutsches Herzzentrum München, Technische Universität, Munich, Germany
| | - Felix Berger
- Klinik für Kinderkardiologie und angeborene Herzfehler, Deutsches Herzzentrum Berlin, Berlin, Germany
| | - Stephan Schubert
- Klinik für Kinderkardiologie und angeborene Herzfehler, Deutsches Herzzentrum Berlin, Berlin, Germany
| | - Mario Carminati
- Department of Paediatric Cardiology and Cardiac Surgery and Adult Congenital Heart Disease, IRCCS Policlinico San Donato, Milan, 20097, Italy
| | - Gianfranco Butera
- Department of Paediatric Cardiology and Cardiac Surgery and Adult Congenital Heart Disease, IRCCS Policlinico San Donato, Milan, 20097, Italy
| | - Jochen Grohmann
- Department of Congenital Heart Defects and Pediatric Cardiology, Heart Center, University of Freiburg, Freiburg, Germany
| | - Rene Höhn
- Department of Congenital Heart Defects and Pediatric Cardiology, Heart Center, University of Freiburg, Freiburg, Germany
| | - Jens Erik Nielsen-Kudsk
- Department of Cardiology-Research, Institute of Clinical Medicine, Aarhus University Hospital Skejby, Aarhus N, DK-8200, Denmark
| | | | - Magnus Settergren
- Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
| | - John D Thomson
- Department of Congenital Cardiology, Leeds General Infirmary, Leeds, United Kingdom
| | - Nicolas Geis
- Department of Cardiology, Angiology, and Pulmology, University of Heidelberg, Heidelberg, Germany
| | - Lars Søndergaard
- The Heart Centre, Rigshospitalet University Hospital, Copenhagen, 2100, Denmark
| |
Collapse
|
2
|
Marmagkiolis K, Cilingiroglu M. Have we found the optimal solution for “Swiss Cheese” ASDs yet? Catheter Cardiovasc Interv 2014; 84:211. [DOI: 10.1002/ccd.25577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Revised: 05/31/2014] [Accepted: 06/14/2014] [Indexed: 11/10/2022]
Affiliation(s)
| | - Mehmet Cilingiroglu
- Koc University, School of Medicine, Istanbul, Turkey
- Arkansas Heart Hospital, Little Rock, AR
| |
Collapse
|
3
|
Lombardi M, Tagliente MR, Pirolo T, Massari E, Milella L, Vairo U. Feasibility and safety of a new generation of gore septal occluder device in children. J Cardiovasc Med (Hagerstown) 2014; 17 Suppl 2:e249-e251. [PMID: 24721761 DOI: 10.2459/jcm.0000000000000036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
AIM Transcatheter closure of an ostium secundum atrial septal defect (ASD) is now considered the standard care for most of children with the appropriate anatomy, and is a relatively well-tolerated procedure to reduce the clinical sequelae of ASD, with a low complication rate. METHODS The present case reports describe our clinical experience of the percutaneous closure of a secundum ASD in 10 children between December 2011 and November 2012, by means of a new generation of device, the GORE Septal Occluder device. RESULTS The implantation was successful in all except two cases, the device being properly placed and deployed without malposition or embolization in the catheterization laboratory. No complications were related to the procedure. The successful implant was confirmed and no major adverse events were documented in the following 3-12 months. CONCLUSION The new GORE Septal Occluder device appears to be a feasible, well-tolerated and successful tool for the closure of an ASD of 15 mm or less in childhood.
Collapse
Affiliation(s)
- Maristella Lombardi
- Department of Pediatric Cardiology, Ospedale Pediatrico Giovanni XXIII, Bari, Italy
| | | | | | | | | | | |
Collapse
|
4
|
Evolving trends in interventional cardiology: endovascular options for congenital disease in adults. Can J Cardiol 2013; 30:75-86. [PMID: 24365192 DOI: 10.1016/j.cjca.2013.11.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2013] [Revised: 11/06/2013] [Accepted: 11/06/2013] [Indexed: 02/06/2023] Open
Abstract
As increasing numbers of patients with congenital heart disease enter adulthood, there is a growing need for minimally invasive percutaneous interventions, primarily to minimize the number of repeated surgeries required by these patients. The use of percutaneous devices is commonplace for the treatment of simple lesions, such as atrial septal defect, patent foramen ovale, patent duct arteriosus, and abnormal vascular connections. There is also substantial experience with device closure of membranous and muscular ventricular septal defects, as well as more complex shunts such as baffle leaks after atrial switch repair and ventricular pseudoaneurysms. An increasing use of covered stents has improved the safety of aortic coarctation, conduit, and branch pulmonary stenosis interventions. Percutaneous pulmonary valve implantation now has an established role in the setting of dysfunctional right ventricle-pulmonary artery conduits or failing bioprosthetic pulmonary valves. Many patients remain unsuitable for percutaneous pulmonary valve implantation because of large diameter "native" outflow tracts, however, various techniques have emerged and multiple devices are in development to provide solutions for these unique anatomic challenges. Hybrid approaches involving use of surgical and transcatheter techniques are increasingly common, serving to optimize efficacy and safety of certain procedures; they depend on a collaborative and collegial relationship between cardiac surgeons and interventionalists that is primarily patient-centred.
Collapse
|
5
|
Freixa X, Ibrahim R, Chan J, Garceau P, Dore A, Marcotte F, Mercier LA, Mongeon FP, Basmadjian A, Khairy P, Asgar AW. Initial clinical experience with the GORE septal occluder for the treatment of atrial septal defects and patent foramen ovale. EUROINTERVENTION 2013; 9:629-35. [DOI: 10.4244/eijv9i5a100] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|